SARS-CoV-2 IgM/IgG Antibody Kit
COVID-19 infection triggers an immune response in the human body, which includes the production of specific antibodies against the SARS-CoV-2 virus. The development of an antibody response to COVID-19 can take days to weeks and may vary significantly among individuals.
Intended Use:
The SARS-CoV-2 IgM/IgG antibody test is a rapid immunochromatographic assay for the qualitative detection of antibodies (IgG and IgM) produced against the SARS-CoV-2 nucleocapsid antigen in human serum, plasma, or whole blood.
• Detection of both IgG and IgM isotypes.
• Compatible with a wide range of sample types, including plasma, serum, capillary blood, or venous blood.
• No cross-reactivity observed with antibodies against other human coronaviruses, other respiratory viruses, or common diseases.
Performance Evaluation:
SARS-CoV-2 IgM
• Positive Percent Agreement: 87.54%
• Negative Percent Agreement: 98.43%
• Overall Percent Agreement: 93.33%
SARS-CoV-2 IgG
• Positive Percent Agreement: 92.88%
• Negative Percent Agreement: 99.06%
• Overall Percent Agreement: 96.17%

Scroll to Top